Dr.Eugene, J. WANG
Founder& CEO, Help Therapeutics Co., Ltd.
Dr. Eugene J. WANG is the CEO of Help Therapeutics Limited, which he founded in 2016. A gold medalist at University, Dr. WANG received his research fellowship training in Mount Sinai School ofMedicine and worked as a clinical cardiologist at The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital, ranked in Top 20 inChina) after earning his PhD from theUniversity of Hong Kong and MD from Capital Medical University. A research scientist in Stem Cell and Regenerative Medicine, Dr. WANG strongly believes that innovative technology in induced pluripotent stem cells (iPSC) development is essential to solve degenerative problems caused by aging-related intractable diseases.
Under Dr. WANG’s leadership, Help Therapeutics has grown to become a globally clinical-stage biopharmaceutical company dedicated to the development of first-in-class iPSC-derived cell therapeutics for heart failure and neurodegenerative diseases. Over the past 6 years, Dr. Wang has led the team to complete world’s First-in-Human trial of induced pluripotent stem cells-based heart repair, which was reported by Nature in 2020.
A serial entrepreneur with a passion for innovative ideas, Dr. WANG is an industrial leader in automatically robotic cell manufacturing system integrated machine learning and data analytics techniques. The multi-scale and high-performing industrial cell production operating to cGMP standards is the first in the world to meet the real-world clinical demand of iPSC-CMs in purity and amount for cell transplantation.
Dr. WANG also spearheads in shaping cardio-regeneration education and policy through his association with several committees in China such as:
- Research fellowship in Science & Technology Institute of National Health Commission of China
- Chair PI ofChina iPSC Model Bank for Intractable Diseases
- ExecutiveDirector of China Stem Cell Industry Alliance
Dr. WANG has been honored by prestigious awards including State’s Key Project of R&D Plan, National NaturalScience Foundation, Leadership ofInnovation Award of the Year, and Best Entrepreneur of JiangsuProvince.
Under Dr. WANG’s leadership, Help Therapeutics has grown to become a globally clinical-stage biopharmaceutical company dedicated to the development of first-in-class iPSC-derived cell therapeutics for heart failure and neurodegenerative diseases. Over the past 6 years, Dr. Wang has led the team to complete world’s First-in-Human trial of induced pluripotent stem cells-based heart repair, which was reported by Nature in 2020.
A serial entrepreneur with a passion for innovative ideas, Dr. WANG is an industrial leader in automatically robotic cell manufacturing system integrated machine learning and data analytics techniques. The multi-scale and high-performing industrial cell production operating to cGMP standards is the first in the world to meet the real-world clinical demand of iPSC-CMs in purity and amount for cell transplantation.
Dr. WANG also spearheads in shaping cardio-regeneration education and policy through his association with several committees in China such as:
- Research fellowship in Science & Technology Institute of National Health Commission of China
- Chair PI ofChina iPSC Model Bank for Intractable Diseases
- ExecutiveDirector of China Stem Cell Industry Alliance
Dr. WANG has been honored by prestigious awards including State’s Key Project of R&D Plan, National NaturalScience Foundation, Leadership ofInnovation Award of the Year, and Best Entrepreneur of JiangsuProvince.
“At Help Therapeutics, webelieve that the best way to realize Affordable Innovation is to enhancesuperior R&D and manufacturing capabilities, combined with our expert teamand partners, value and support at every stage of the regenerative journey tobring the next generation advanced therapies to patients in need.”
Our team
Dr.Eugene, J. WANG
Founder & CEO, Help Therapeutics Co., Ltd.
Achievements of
Stem Cell Innovation
🏅️
Two grants of the State National Key R&D Programs
2022: Vascular reconstraction and its application in ischemic heart failure based on stem cell and biomaterial engineering
2017: Stem cell therapy for heart failure
🏅️
The Technology & Innovation Exhibition of China 13th Five-Year Plan (2021)
Cardio-regeneration cell therapy
Integrated multi-scale & automatic cell-foundry platform
🏅️
Progress of HiCM-188
The first domestic iPSC-driven clinical trial filed by National Health Commission of China: MR-32-21-014649 IND approval in Jan 2023
Collaborator: Prof. Dongjin WANG, Nanjing Drum Tower Hospital
🏅️
The Project of iPSC Preservation Study collaborated with S&T institute of China National Health Commission
The standardized construction and application of human iPSC-derived cell model bank
